BIONTECH SE-ADR (22UA.DE) Stock Price, Quote, News and Overview
FRA:22UA - Deutsche Boerse Ag - US09075V1026 - ADR - Currency: EUR
22UA.DE Quote, Performance and Key Statistics
FRA:22UA (4/25/2025, 5:28:42 PM)
102.2
0 (0%)
The current stock price of 22UA.DE is 102.2 EUR. In the past month the price increased by 12.31%. In the past year, price increased by 24.03%.
22UA.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.12 | 285.34B | ||
| AMG.DE | AMGEN INC | 14.06 | 131.64B | ||
| GIS.DE | GILEAD SCIENCES INC | 22.38 | 112.98B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 1728.6 | 111.10B | ||
| ARGX.BR | ARGENX SE | 352.5 | 32.72B | ||
| IDP.DE | BIOGEN INC | 7.29 | 15.44B | ||
| 0QF.DE | MODERNA INC | N/A | 9.46B | ||
| 1MRNA.MI | MODERNA INC | N/A | 9.08B | ||
| BIO.DE | BIOTEST AG | 24.8 | 1.68B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.54B | ||
| BIO3.DE | BIOTEST AG-VORZUGSAKTIEN | 17.54 | 1.19B | ||
| AZT.OL | ARCTICZYMES TECHNOLOGIES ASA | 124.29 | 888.62M |
Related stock screener links
About 22UA.DE
Company Profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,772 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company Info
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ DE
Employees: 6133
Company Website: https://www.biontech.com/
Investor Relations: https://investors.biontech.de/
Phone: 4949613190840
BIONTECH SE-ADR / 22UA.DE FAQ
What is the stock price of BIONTECH SE-ADR today?
The current stock price of 22UA.DE is 102.2 EUR.
What is the ticker symbol for BIONTECH SE-ADR stock?
The exchange symbol of BIONTECH SE-ADR is 22UA and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 22UA.DE stock listed?
22UA.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for BIONTECH SE-ADR stock?
28 analysts have analysed 22UA.DE and the average price target is 125.88 EUR. This implies a price increase of 23.17% is expected in the next year compared to the current price of 102.2. Check the BIONTECH SE-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIONTECH SE-ADR worth?
BIONTECH SE-ADR (22UA.DE) has a market capitalization of 24.57B EUR. This makes 22UA.DE a Large Cap stock.
How many employees does BIONTECH SE-ADR have?
BIONTECH SE-ADR (22UA.DE) currently has 6133 employees.
What are the support and resistance levels for BIONTECH SE-ADR (22UA.DE) stock?
BIONTECH SE-ADR (22UA.DE) has a support level at 81.19 and a resistance level at 102.21. Check the full technical report for a detailed analysis of 22UA.DE support and resistance levels.
Is BIONTECH SE-ADR (22UA.DE) expected to grow?
The Revenue of BIONTECH SE-ADR (22UA.DE) is expected to decline by -20.78% in the next year. Check the estimates tab for more information on the 22UA.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIONTECH SE-ADR (22UA.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of 22UA.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of 22UA.DE, evaluating the profitability, health, valuation and growth aspects
- BIONTECH SE-ADR (22UA.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIONTECH SE-ADR (22UA.DE) Sales and EPS estimates to see what analysts future expectations are.
- BIONTECH SE-ADR (22UA.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIONTECH SE-ADR (22UA.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIONTECH SE-ADR (22UA.DE) Stock Chart to make your own analysis
- BIONTECH SE-ADR (22UA.DE) Latest news and press-releases to stay up to date.
Does BIONTECH SE-ADR (22UA.DE) stock pay dividends?
22UA.DE does not pay a dividend.
When does BIONTECH SE-ADR (22UA.DE) report earnings?
BIONTECH SE-ADR (22UA.DE) will report earnings on 2025-05-05, before the market open.
What is the Price/Earnings (PE) ratio of BIONTECH SE-ADR (22UA.DE)?
BIONTECH SE-ADR (22UA.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.78).
22UA.DE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to 22UA.DE. When comparing the yearly performance of all stocks, 22UA.DE is one of the better performing stocks in the market, outperforming 80.75% of all stocks.
22UA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 22UA.DE. While 22UA.DE seems to be doing ok healthwise, there are quite some concerns on its profitability.
22UA.DE Financial Highlights
Over the last trailing twelve months 22UA.DE reported a non-GAAP Earnings per Share(EPS) of -2.78. The EPS decreased by -172.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.95% | ||
| ROE | -3.43% | ||
| Debt/Equity | 0.01 |
22UA.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to 22UA.DE. The Buy consensus is the average rating of analysts ratings from 28 analysts.
For the next year, analysts expect an EPS growth of -90.43% and a revenue growth -20.78% for 22UA.DE